Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Fetal and neonatal alloimmune thrombocytopenia : recommendations for evidence-based practice, an international approach. / International Collaboration for Transfusion Medicine Guidelines (ICTMG); Lieberman, Lani; Greinacher, Andreas; Murphy, Michael F.; Bussel, James; Bakchoul, Tamam; Corke, Stacy; Kjaer, Mette; Kjeldsen-Kragh, Jens; Bertrand, Gerald; Oepkes, Dick; Baker, Jillian M.; Hume, Heather; Massey, Edwin; Kaplan, Cécile; Arnold, Donald M.; Baidya, Shoma; Ryan, Greg; Savoia, Helen; Landry, Denise; Shehata, Nadine.

I: British Journal of Haematology, Vol. 185, Nr. 3, 2019, s. 549-562.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

International Collaboration for Transfusion Medicine Guidelines (ICTMG), Lieberman, L, Greinacher, A, Murphy, MF, Bussel, J, Bakchoul, T, Corke, S, Kjaer, M, Kjeldsen-Kragh, J, Bertrand, G, Oepkes, D, Baker, JM, Hume, H, Massey, E, Kaplan, C, Arnold, DM, Baidya, S, Ryan, G, Savoia, H, Landry, D & Shehata, N 2019, 'Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach', British Journal of Haematology, vol. 185, nr. 3, s. 549-562. https://doi.org/10.1111/bjh.15813

APA

International Collaboration for Transfusion Medicine Guidelines (ICTMG), Lieberman, L., Greinacher, A., Murphy, M. F., Bussel, J., Bakchoul, T., ... Shehata, N. (2019). Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. British Journal of Haematology, 185(3), 549-562. https://doi.org/10.1111/bjh.15813

CBE

International Collaboration for Transfusion Medicine Guidelines (ICTMG), Lieberman L, Greinacher A, Murphy MF, Bussel J, Bakchoul T, Corke S, Kjaer M, Kjeldsen-Kragh J, Bertrand G, Oepkes D, Baker JM, Hume H, Massey E, Kaplan C, Arnold DM, Baidya S, Ryan G, Savoia H, Landry D, Shehata N. 2019. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. British Journal of Haematology. 185(3):549-562. https://doi.org/10.1111/bjh.15813

MLA

Vancouver

International Collaboration for Transfusion Medicine Guidelines (ICTMG), Lieberman L, Greinacher A, Murphy MF, Bussel J, Bakchoul T et al. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. British Journal of Haematology. 2019;185(3):549-562. https://doi.org/10.1111/bjh.15813

Author

International Collaboration for Transfusion Medicine Guidelines (ICTMG) ; Lieberman, Lani ; Greinacher, Andreas ; Murphy, Michael F. ; Bussel, James ; Bakchoul, Tamam ; Corke, Stacy ; Kjaer, Mette ; Kjeldsen-Kragh, Jens ; Bertrand, Gerald ; Oepkes, Dick ; Baker, Jillian M. ; Hume, Heather ; Massey, Edwin ; Kaplan, Cécile ; Arnold, Donald M. ; Baidya, Shoma ; Ryan, Greg ; Savoia, Helen ; Landry, Denise ; Shehata, Nadine. / Fetal and neonatal alloimmune thrombocytopenia : recommendations for evidence-based practice, an international approach. I: British Journal of Haematology. 2019 ; Vol. 185, Nr. 3. s. 549-562.

RIS

TY - JOUR

T1 - Fetal and neonatal alloimmune thrombocytopenia

T2 - British Journal of Haematology

AU - International Collaboration for Transfusion Medicine Guidelines (ICTMG)

AU - Lieberman, Lani

AU - Greinacher, Andreas

AU - Murphy, Michael F.

AU - Bussel, James

AU - Bakchoul, Tamam

AU - Corke, Stacy

AU - Kjaer, Mette

AU - Kjeldsen-Kragh, Jens

AU - Bertrand, Gerald

AU - Oepkes, Dick

AU - Baker, Jillian M.

AU - Hume, Heather

AU - Massey, Edwin

AU - Kaplan, Cécile

AU - Arnold, Donald M.

AU - Baidya, Shoma

AU - Ryan, Greg

AU - Savoia, Helen

AU - Landry, Denise

AU - Shehata, Nadine

PY - 2019

Y1 - 2019

N2 - Fetal and neonatal alloimmune thrombocytopenia (FNAIT) may result in severe bleeding, particularly fetal and neonatal intracranial haemorrhage (ICH). As a result, FNAIT requires prompt identification and treatment; subsequent pregnancies need close surveillance and management. An international panel convened to develop evidence-based recommendations for diagnosis and management of FNAIT. A rigorous approach was used to search, review and develop recommendations from published data for: antenatal management, postnatal management, diagnostic testing and universal screening. To confirm FNAIT, fetal human platelet antigen (HPA) typing, using non-invasive methods if quality-assured, should be performed during pregnancy when the father is unknown, unavailable for testing or heterozygous for the implicated antigen. Women with a previous child with an ICH related to FNAIT should be offered intravenous immunoglobulin (IVIG) infusions during subsequent affected pregnancies as early as 12 weeks gestation. Ideally, HPA-selected platelets should be available at delivery for potentially affected infants and used to increase the neonatal platelet count as needed. If HPA-selected platelets are not immediately available, unselected platelets should be transfused. FNAIT studies that optimize antenatal and postnatal management, develop risk stratification algorithms to guide management and standardize laboratory testing to identify high risk pregnancies are needed.

AB - Fetal and neonatal alloimmune thrombocytopenia (FNAIT) may result in severe bleeding, particularly fetal and neonatal intracranial haemorrhage (ICH). As a result, FNAIT requires prompt identification and treatment; subsequent pregnancies need close surveillance and management. An international panel convened to develop evidence-based recommendations for diagnosis and management of FNAIT. A rigorous approach was used to search, review and develop recommendations from published data for: antenatal management, postnatal management, diagnostic testing and universal screening. To confirm FNAIT, fetal human platelet antigen (HPA) typing, using non-invasive methods if quality-assured, should be performed during pregnancy when the father is unknown, unavailable for testing or heterozygous for the implicated antigen. Women with a previous child with an ICH related to FNAIT should be offered intravenous immunoglobulin (IVIG) infusions during subsequent affected pregnancies as early as 12 weeks gestation. Ideally, HPA-selected platelets should be available at delivery for potentially affected infants and used to increase the neonatal platelet count as needed. If HPA-selected platelets are not immediately available, unselected platelets should be transfused. FNAIT studies that optimize antenatal and postnatal management, develop risk stratification algorithms to guide management and standardize laboratory testing to identify high risk pregnancies are needed.

KW - fetal

KW - Guideline

KW - haematology

KW - HPA-1a

U2 - 10.1111/bjh.15813

DO - 10.1111/bjh.15813

M3 - Article

VL - 185

SP - 549

EP - 562

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -